GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

被引：0
|
作者：
Conduit, Ciara
Mak, Blossom
Qu, Wenjia
Yeung, Theresa
Bressel, Mathias
Cusick, Thomas
Dhillon, Haryana M.
Lourenco, Richard De Abreu
Underhill, Craig
Torres, Javier
Crumbaker, Megan
Honeyball, Florian
Linton, Anthony
Sewak, Sanjeev
Chau, Nguyen Minh Hieu
Allen, Ray
Davis, Ian D.
Clark, Susan J.
Horvath, Lisa
Mahon, Kate Lynette
机构：
[1] Australian &New Zealand Urogenital & Prostate ANZ, Camperdown, NSW, Australia
[2] Chris OBrien Lifehouse, Sydney, NSW, Australia
[3] Garvan Inst Med Res, Sydney, NSW, Australia
[4] Peter Maccallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Univ Sydney, Sch Psychol, Psycho Oncol Cooperat Res Grp,Fac Sci, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW, Australia
[6] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia
[7] Albury Wodonga Reg Canc Ctr, Border Med Oncol Res Unit, Albury, NSW, Australia
[8] Univ New South Wales, Rural Med Sch, Albury, NSW, Australia
[9] Goulburn Valley Hlth, Shepparton, Australia
[10] Dubbo Base Hosp, Dubbo, Australia
[11] Univ Sydney, Sydney, NSW, Australia
[12] Peninsula & South East Oncol, Frankston, Australia
[13] Latrobe Reg Hosp, Traralgon, Australia
[14] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5099
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer.
    Cash, Hannes
    Steiner, Ursula
    Heidenreich, Axel
    Klotz, Theodor
    Melchior, Sebastian
    Albers, Peter
    Martus, Peter
    Hinz, Stefan
    Magheli, Ahmed
    Kempkensteffen, Carsten
    Miller, Kurt
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [23] Updated results: A phase InIa randomized trial of radium-223+docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.
    Morris, Michael J.
    Loriot, Yohann
    Sweeney, Christopher
    Fizazi, Karim
    Ryan, Charles J.
    Shevrin, Daniel H.
    Antonarakis, Emmanuel S.
    Reeves, John
    Chandrawansa, Kumari
    Kornacker, Martin
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Healy, Patrick
    Barak, Ian
    Winters, Carolyn
    Anand, Monika
    Wilder, Rhonda
    Klein, Melissa
    Martinez, Elia
    Nixon, Andrew B.
    Harrison, Michael R.
    Szmulewitz, Russell
    Armstrong, Andrew J.
    PROSTATE, 2019, 79 (15): : 1752 - 1761
  • [25] A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial
    Bouman-Wammes, Esther W.
    van den Berg, H. Pieter
    de Munck, Linda
    Beeker, Aart
    Smorenburg, Carolien H.
    Vervenne, Walter L.
    Coenen, Juleon L. L. M.
    Verheul, Henk M. W.
    Gerritsen, Winald R.
    Van den Eertwegh, Alfons J. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 1 - 9
  • [26] Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
    Vaishampayan, Ulka
    Shevrin, Daniel
    Stein, Mark
    Heilbrun, Lance
    Land, Susan
    Stark, Karri
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth
    Smith, Daryn
    Fontana, Joseph
    UROLOGY, 2015, 86 (06) : 1206 - 1211
  • [27] Randomized phase II trial of docetaxel plus prednisolone with or without androgen deprivation treatment in castration-resistant prostate cancer.
    Jeong, Jae Ho
    Hyun, Hyejung
    Jeong, In Gab
    Hong, Jun Hyuk
    Ahn, Hanjong
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [28] Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE)
    Cash, Hannes
    Steiner, Ursula
    Heidenreich, Axel
    Klotz, Theodor
    Albers, Peter
    Melchior, Sebastian
    Martus, Peter
    Fuller, Florian
    Magheli, Ahmed
    Hinz, Stefan
    Kempkensteffen, Carsten
    Miller, Kurt
    BJU INTERNATIONAL, 2018, 122 (05) : 774 - 782
  • [29] Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Tannock, Ian
    Fizazi, Karim
    Ivanov, Sergey
    Thellenberg-Karlsson, Camilla
    Flechon, Aude
    Skoneczna, Iwona Anna
    Orlandi, Francisco Jorquera
    Gravis, Gwenaelle
    Matveev, Vsevolod
    Bavbek, Sevil E.
    Gil, Thierry
    Viana, Luciano S.
    Aren, Osvaldo
    Karyakin, Oleg
    Elliott, Tony
    Birtle, Alison J.
    Magherini, Emmanuelle
    Petrylak, Daniel Peter
    Tombal, Bertrand
    Rosenthal, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Laber, Damian A.
    Eatrides, Jennifer
    Jaglal, Michael V.
    Haider, Mintallah
    Visweshwar, Nathan
    Patel, Ankita
    MEDICAL ONCOLOGY, 2020, 37 (10)
12345